Armata Pharmaceuticals, Inc. (ARMP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 4 | 6 | 5 | 5 | 5 | 3 | 4 |
| Operating profit | $m | -31 | -41 | ||||||
| Net profit | $m | -22 | -23 | -37 | -69 | -19 | -174 | -192 | -68 |
| EPS reported | $ | -4.80 | -7.59 | ||||||
| Operating cashflow per share | $ | -0.71 | -0.69 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.73 | -0.70 | ||||||
| Free cash flow | $m | -26 | -26 | ||||||
| Net debt | $m | 248 | 260 | ||||||
| Book value equity | $m | -219 | -231 | ||||||
| Book value per share | $ | -6.03 | -3.73 | ||||||
| Number of shares | m | 36.24 | 62.04 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -1.04 | -0.98 | ||||||
| P/S LTM | x | 46.41 | 68.99 | ||||||
| P/FCF LTM | x | -8.65 | -8.82 | ||||||
| EV/EBITDA LTM | x | -3.26 | -3.00 | ||||||
| EV/Sales LTM | x | 103.37 | 152.89 | ||||||
| Earnings Yield LTM | % | -76.37% | -89.55% | ||||||
| FCF Yield | % | -11.56% | -11.33% | ||||||
| Quality | |||||||||
| ROE | % | +79.51% | +89.70% | ||||||
| ROIC | % | -43.07% | -47.40% | ||||||
| Operating margin | % | -6.37% | -12.34% | ||||||
| Gross margin | % | +68.78% | +68.23% | ||||||
| FCF/Sales | % | -536.40% | -781.87% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -5.22% | -36.24% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.09 | -0.08 | ||||||
| Net Debt/EBITDA | x | -1.79 | -1.72 | ||||||
| EBIT/Net interest | x | -1.88 | -1.90 | ||||||
| Net debt/market cap | % | +1.13% | +1.34% | ||||||
| Net debt/Equity | x | -1.14 | -1.12 | ||||||
| Gross debt/equity | x | -1.32 | -1.36 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Armata Pharmaceuticals, Inc. (ARMP)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free